Pharma companies press on in fight against drug resistance, yet lag in access to antibiotics.
The 2021 AMR Benchmark evaluates 17 companies with a major stake in the anti-infectives space, including large research-based companies and generic medicine manufacturers. By comparing how they perform across a set of 20 metrics, the Benchmark tracks the progress and gaps in their efforts to keep medicines and vaccines available, despite the rise of drug resistance.
Large R&D-based companies
Generic medicine manufacturers
GSK maintains lead in antibacterial and antifungal R&D to target priority pathogens
GSK's pipeline is the largest evaluated, with 31 projects in the pipeline. It addresses more pathogens designated as ‘critical’ and/or ‘urgent’ threats, and has most vaccines projects underway.
R&D pipeline grows, but remains small overall
Since the previous analysis, 22 projects have left the pipeline, but there have been 38 additions. As a result, the pipeline has modestly increased in size, by 15 projects, from 77 to 92.
Sustained R&D for AMR from most companies
Only one of the eight companies evaluated is not currently active in R&D targeting priority pathogens. The remaining seven have sustained their involvement, and several have expanded their pipelines. Pfizer and GSK stand out for adding five and four projects, respectively.
Which pathogens are receiving most attention in R&D
The World Health Organization and US Centers for Disease Control have identified the most dangerous pathogens due to resistance. The eight large research-based companies evaluated are developing 92 medicine and vaccine projects that target them.